Z16.34
Resistance to antimycobacterial drug(s)
Clinical Classification Guidelines
Inclusion Terms
- Resistance to tuberculostatics
Medical Intelligence & Overview
Resistance to antimycobacterial drugs, coded as Z16.34 in the ICD-10 classification, refers to a condition where the tuberculosis bacteria no longer respond to medications designed to treat the infection. This resistance can complicate treatment, extend the duration of therapy, and increase the risk of transmission and adverse health outcomes. Understanding this condition is essential for patients and healthcare providers managing tuberculosis (TB) treatment.
Causes & Symptoms
Clinical Causes: Inadequate or incomplete treatment of TB, leading to survival of resistant bacteria Incorrect dosage or poor adherence to prescribed medication regimens Use of low-quality or substandard medications Genetic mutations within Mycobacterium tuberculosis strains that confer drug resistance Transmission of drug-resistant TB strains from person to person
Key Symptoms: Persistent cough lasting three weeks or longer Coughing up blood or sputum Chest pain or discomfort Unintended weight loss Night sweats Fever and chills Fatigue and weakness Loss of appetite
Diagnostic & Treatment
Diagnosis Path: Microscopic examination of sputum samples for TB bacteria Culture tests to grow bacteria and determine drug susceptibility Molecular tests (such as Xpert MTB/RIF) to detect resistance mutations quickly Chest imaging, like X-rays, to identify lung abnormalities
Treatment Protocols: Use of second-line medications that are effective against resistant strains Prolonged treatment duration, often 9- 12 months or longer Regular monitoring for medication side effects Combination therapy to prevent further resistance development Close follow-up with healthcare providers to ensure adherence
Clinical Advice & FAQs
Billing Guidance
Is Z16.34 a billable ICD-10 code?
Yes, Z16.34 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Z16.34?
Clinical documentation must specify the nature of Resistance to antimycobacterial drug(s) and any associated comorbidities for accurate reporting.
Cite this Clinical Reference